PharmaCyte Biotech increases stake in TNF Pharmaceuticals, bolstering the licensing of LightSolver’s light‑based compute accelerator in cryptocurrency and blockchain applications. PharmaCyte reported over USD 55 million in total assets as of April 30, 2025 and is actively pursuing broader investment avenues to enhance shareholder value.
Strategic Capital Infusion Fuels Emerging Crypto Infrastructure
PharmaCyte Biotech has allocated an additional USD 3 million to increase its stake in TNF Pharmaceuticals. This investment underpins TNF’s acquisition of a license for pioneering processing accelerator technology developed by LightSolver, a recognized 2025 Technology Pioneer by the World Economic Forum and featured in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies.
Revolutionary Light‑Based Processing Promises Speed and Sustainability
LightSolver’s processing accelerator, leveraging light rather than traditional electronic computation, aims to deliver a 90% reduction in energy consumption while surpassing the speed of GPUs, quantum systems, and high-performance computing platforms. TNF anticipates rebranding—including a possible name and ticker change—to reflect its pivot toward blockchain and cryptocurrency infrastructure.
Robust Financial Position Enables Strategic Diversification
Despite this targeted investment, PharmaCyte remains financially solid, with over USD 55 million in assets reported as of April 30, 2025. The company continues to evaluate further opportunities to diversify its portfolio and drive long‑term value creation.
Safe Harbor Considerations
This announcement contains forward‑looking statements under the Private Securities Litigation Reform Act of 1995. The actual outcomes may differ due to risks including TNF’s capacity to effectively deploy LightSolver’s technology, execution of PharmaCyte’s portfolio expansion strategy, and broader market conditions. For more information, see filings on Forms 10‑K and 10‑Q. These statements are current as of the release date (September 2, 2025) and PharmaCyte assumes no obligation to update them except as legally required
